SELLAS Life Sciences (SLS) Amortization of Deferred Charges (2017 - 2021)
SELLAS Life Sciences (SLS) reported Amortization of Deferred Charges of $846000.0 for Q1 2021, up 4352.63% quarter-over-quarter from $19000.0 in Q3 2018.
SELLAS Life Sciences (SLS) Amortization of Deferred Charges (2017 - 2021) Analysis & Trends
SELLAS Life Sciences (SLS) has 3 years of Amortization of Deferred Charges data on file, last reported at $846000.0 in Q1 2021.
- Amortization of Deferred Charges for Q1 2021 came in at $846000.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2021 was $846000.0 (changed N/A YoY), and the FY2020 annual result was $282000.0, changed N/A from the prior year.
- Amortization of Deferred Charges climbed to $846000.0 in Q1 2021 per SLS's latest filing, from $19000.0 in the prior quarter.
- Over five years, Amortization of Deferred Charges peaked at $846000.0 in Q1 2021 and troughed at -$258000.0 in Q4 2017.
- A 3-year average of $163333.3 and a median of $57500.0 in 2018 frame the typical range for Amortization of Deferred Charges.
- On a YoY basis, Amortization of Deferred Charges climbed as much as 63.18% in 2018 and fell as far as 63.18% in 2018.
- A 3-year view of Amortization of Deferred Charges shows it stood at -$258000.0 in 2017, then soared by 107.36% to $19000.0 in 2018, then surged by 4352.63% to $846000.0 in 2021.
- Business Quant data shows SLS's Amortization of Deferred Charges at $846000.0 in Q1 2021, $19000.0 in Q3 2018, and $95000.0 in Q2 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | SELLAS Life Sciences | 1.39 Bn | 1.39 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2021 | 846,000.00 |
| Mar 31, 2021 | 846,000.00 |
| Sep 30, 2018 | 19,000.00 |
| Sep 30, 2018 | 19,000.00 |
| Jun 30, 2018 | 95,000.00 |
| Jun 30, 2018 | 95,000.00 |
| Mar 31, 2018 | 20,000.00 |
| Mar 31, 2018 | 20,000.00 |
| Dec 31, 2017 | -258,000.00 |
| Dec 31, 2017 | -258,000.00 |
| Jun 30, 2017 | 258,000.00 |
| Jun 30, 2017 | 258,000.00 |